OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
The Target Discovery Institute, Oxford (www.tdi.ox.ac.uk/home) is a research facility dedicated to identifying drug targets, molecules or molecular interactions at a critical point in a disease-causing pathway that are predicted to being amenable to therapeutic manipulation. The instituted has been operating since 2013 in the NDMRB on the Old Road Campus and is directed by Professor Sir Peter Ratcliffe. The TDI consists of eight Principal Investigators with particular expertise in High Throughput screening (Ebner, Fedorov), Functional Genomics (Nijman), Chemical Biology (Huber), Medicinal Chemistry (Brennan), Proteomics (Kessler), and Biomedical Imaging (Rittscher).
In this talk, we will highlight a number of techniques we use to advance target discovery including, cell based screening (including CRISPR/Cas9), chemo-proteomics, chemical biology and multi-omics with group leaders, Ebner, Kessler and Huber. We will also discuss some of the technology platforms we employ, some recent success stories and finally, discuss opportunities for scientific collaboration with the TDI.